Drug intelligence / Profile preview

chidantong

Development stage: Unknown
Lead developer: Chia Tai-Tianqing Pharmaceutical Group
Modality: Small Molecules
Administration: Oral

Overview

Chidantong (also known as Chidan Maitong) is a Traditional Chinese Medicine (TCM) capsule developed by Jiangsu Chia Tai Tianqing Pharmaceutical. It is indicated for the treatment of atherosclerotic thrombotic cerebral infarction and ischemic stroke during the recovery phase, particularly for patients presenting with the 'blood stasis obstructing collaterals' pattern. The formulation is designed to promote blood circulation and resolve stasis to improve neurological outcomes. It has been evaluated in a Phase 3 randomized, double-blind clinical trial in China, where its efficacy and safety were compared against ginkgo leaf capsules in patients recovering from ischemic stroke.

Brand names: ChidantongChidan Maitong
Other names: Chidan Maitong capsule

Beyond the preview

Go deeper on chidantong.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on chidantong.

Explore the full profile